ETHYL 4-[(1-BENZYLINDOL-2-YL)METHOXY]BENZOATE


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	WDTNYGXFLDJQMZ-UHFFFAOYSA-N
Smiles	CCOC(=O)c1ccc(OCc2cc3ccccc3n2Cc4ccccc4)cc1
InChI	InChI=1S/C25H23NO3/c1-2-28-25(27)20-12-14-23(15-13-20)29-18-22-16-21-10-6-7-11-24(21)26(22)17-19-8-4-3-5-9-19/h3-16H,2,17-18H2,1H3

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C25H23NO3
Molecular Weight	385.46
AlogP	5.76
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	8.0
Polar Surface Area	40.46
Molecular species	None
Aromatic Rings	4.0
Heavy Atoms	29.0

Assay Description	Organism	Bioactivity
Juvenile hormone activity in allatectomized fourth-instar larvae of Bombyx mori assessed as number of larvae transformed into larval-pupal intermediate at 40 ug/larvae topically applied to the dorsal abdomen	Bombyx mori	None
Antijuvenile hormone activity in third-instar larvae of Bombyx mori assessed as induction of precocious metamorphosis at 40 ug/larvae topically applied to the dorsal abdomen	Bombyx mori	84.0 %
Antijuvenile hormone activity in third-instar larvae of Bombyx mori assessed as induction of precocious metamorphosis at 10 ug/larvae topically applied to the dorsal abdomen	Bombyx mori	73.0 %
Antijuvenile hormone activity in third-instar larvae of Bombyx mori assessed as induction of precocious metamorphosis at 1 ug/larvae topically applied to the dorsal abdomen	Bombyx mori	73.0 %

Cross References

Resources	Reference
ChEMBL	CHEMBL2271350

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).